Keyphrases
Glucagon-like
100%
Receptor Agonist
100%
A1 Receptor
100%
Weight Loss
100%
Benefit-risk Assessment
100%
Liraglutide
60%
Lifestyle Modification
60%
Semaglutide
60%
Anti-obesity
40%
Placebo
40%
Comorbidity
40%
Pharmacotherapy
20%
Obesity Prevalence
20%
Long-term Efficacy
20%
Adverse Events
20%
Long Half-life
20%
Long-term Safety
20%
Once-daily
20%
Combinational Therapy
20%
Liraglutide 3.0 Mg
20%
Post-marketing Surveillance
20%
Obesity
20%
Massive Weight Loss
20%
Gastrointestinal Diseases
20%
Weight Reduction
20%
Risk-benefit
20%
Safety Concerns
20%
Clinically Significant
20%
Energy Homeostasis
20%
Safety Profile
20%
Average Weight
20%
Non-invasive Treatment
20%
Receptor Affinity
20%
Gut Hormones
20%
Head-to-head Comparison
20%
Medicine and Dentistry
Ibuprofen
100%
Liraglutide
100%
Glucagon-Like Peptide-1 Agonist
100%
Lifestyle Modification
75%
Semaglutide
75%
Antiobesity Drugs
50%
Comorbidity
50%
Placebo
50%
Body Weight Loss
50%
Drug Therapy
25%
Receptor Affinity
25%
Non Invasive Procedure
25%
Gastrointestinal Disease
25%
Gastrointestinal Hormone
25%
Homeostasis
25%
Adverse Event
25%
Prevalence
25%
Pharmacology, Toxicology and Pharmaceutical Science
Liraglutide
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Ibuprofen
100%
Semaglutide
75%
Placebo
50%
Comorbidity
50%
Antiobesity Drugs
50%
Postmarketing Surveillance
25%
Receptor
25%
Adverse Event
25%
Gastrointestinal Disease
25%
Gastrointestinal Hormone
25%
Prevalence
25%
Pharmacotherapy
25%